Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
Abstract The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of NVAF patients newly initiating apixaban or warfarin from January 1, 2013 to September 30, 2015. After 1:1 warfarin-apixaban propensity score matching (PSM) within each database, the resulting patient records were pooled. Kaplan-Meier curves and Cox proportional hazards models were used to estimate the cumulati...
Source: Thrombosis and Haemostasis - March 15, 2017 Category: Hematology Authors: Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GY Tags: Thromb Haemost Source Type: research

Shear sensitive nanocapsule drug release for site specific inhibition of occlusive thrombus formation.
CONCLUSIONS: Targeted delivery of eptifibatide by shear-sensitive nanocapsules offers site specific antiplatelet potential and may form a basis for developing more potent and safer antiplatelet drugs. This article is protected by copyright. All rights reserved. PMID: 28267256 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 6, 2017 Category: Hematology Authors: Molloy CP, Yao Y, Kammoun H, Bonnard T, Hoefer T, Alt K, Tovar-Lopez F, Rosengarten G, Ramsland PA, van der Meer AD, van den Berg A, Murphy AJ, Hagemeyer CE, Peter K, Westein E Tags: J Thromb Haemost Source Type: research

A First-in-human Study of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
CONCLUSIONS: The novel fibrinolysis-enhancing agent DS-1040 has favorable PK/PD properties and safety profile, which warrants further clinical development. This article is protected by copyright. All rights reserved. PMID: 28211169 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 16, 2017 Category: Hematology Authors: Zhou J, Kochan J, Yin O, Warren V, Zamora C, Atiee G, Pav J, Orihashi Y, Vashi V, Dishy V Tags: J Thromb Haemost Source Type: research

Maresin 1 induces a novel pro-resolving phenotype in human platelets.
CONCLUSIONS: These data support the concept that SPMs differentially regulate platelet function and may represent a novel class of antiplatelet agents. SPMs also may play an important role in the resolution of inflammation in cardiovascular diseases. This article is protected by copyright. All rights reserved. PMID: 28079976 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 11, 2017 Category: Hematology Authors: Lannan KL, Spinelli SL, Blumberg N, Phipps RP Tags: J Thromb Haemost Source Type: research

A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
ieber J, Mudra H, Hausleiter J, Huber K, Neumann FJ, Koltowski L, Huczek Z, Mehilli J, Massberg S, TROPICAL-ACS Investigators Abstract Outcomes of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) have been significantly improved with the use of potent P2Y12 receptor inhibitors like prasugrel. While most of the ischaemic risk reduction for prasugrel versus clopidogrel was demonstrated in the early treatment period, the risk of bleeding became particularly prominent during the chronic course of therapy. It may therefore be a valid approach to substitute prasugrel for clopido...
Source: Thrombosis and Haemostasis - September 21, 2016 Category: Hematology Authors: Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Gori T, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Thalmeier A, Löw A, Holdt L, Teupser D, Ince H, Felix SB, Parma R, Malek L, Horstkotte J, Baylacher M, Schwinger R, Tags: Thromb Haemost Source Type: research

Optimising stroke prevention in elderly patients with atrial fibrillation.
This article is protected by copyright. All rights reserved. PMID: 27557552 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 24, 2016 Category: Hematology Authors: Lip GY Tags: J Thromb Haemost Source Type: research

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Abstract In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited data on the comparative risks of major bleeding among newly anticoagulated NVAF patients who initiate warfarin, apixaban, dabigatran, or rivaroxaban, when used in 'real world' clinical practice. The study used the Truven MarketScan® Commercial & Medicare supplemental US claims database. NVAF patients aged ≥18 years newly prescribed an oral anticoagulant 01JAN2013-31DEC2014, with a ≥1-year baseline period, were in...
Source: Thrombosis and Haemostasis - August 18, 2016 Category: Hematology Authors: Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M Tags: Thromb Haemost Source Type: research

Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
This report is based on findings from the Anticoagulation Education Task Force, which brought together patient groups and professionals representing different medical specialties with an interest in patient safety and expertise in AF, VTE, stroke, anticoagulation, and reversal agents, to discuss the current status of anticoagulation reversal and fundamental changes in management of bleeding associated with DOACs occasioned by the approval of idarucizumab, a specific reversal agent for dabigatran, as well as recent clinical data on specific reversal agents for factor Xa inhibitors. Recommendations are given for when there i...
Source: Thrombosis and Haemostasis - August 3, 2016 Category: Hematology Authors: Ageno W, Büller HR, Falanga A, Hacke W, Hendriks J, Lobban T, Merino J, Milojevic IS, Moya F, van der Worp HB, Randall G, Tsioufis K, Verhamme P, Camm AJ Tags: Thromb Haemost Source Type: research

Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Abstract In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when compared to warfarin. However, clinical trials are not very representative of the real-world setting. We aimed to assess the performance of dabigatran in real-world patients with atrial fibrillation (AF) by means of a systematic review and meta-analysis of observational comparison studies with vitamin K antagonists (VKA). We searched PubMed, Embase and Scopus databases until November 2015 and selected studies according to the following criteria: observational study performed with nonvalvular AF patients; reporting...
Source: Thrombosis and Haemostasis - July 27, 2016 Category: Hematology Authors: Carmo J, Moscoso Costa F, Ferreira J, Mendes M Tags: Thromb Haemost Source Type: research

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation: comment.
This article is protected by copyright. All rights reserved. PMID: 27431450 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 18, 2016 Category: Hematology Authors: Mantha S, Moll S, Hilden P, Devlin S, Rose A Tags: J Thromb Haemost Source Type: research

Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation.
Abstract In patients with acute stroke and atrial fibrillation (AF), the risk of early recurrence has been reported to range between 0.1 % and 1.3 % per day. Anticoagulants are the most effective therapy for the prevention of recurrent ischaemic stroke in these patients, but randomised clinical trials have failed to produce any evidence supporting the administration of heparin within 48 hours from stroke onset as it has been associated with a non-significant reduction in the recurrence of ischaemic stroke, no substantial reduction in death and disability, and an increase in intracranial bleeding. As early haem...
Source: Thrombosis and Haemostasis - June 22, 2016 Category: Hematology Authors: Paciaroni M, Agnelli G, Ageno W, Caso V Tags: Thromb Haemost Source Type: research

Bleeding Risk Assessment in Atrial Fibrillation: Observations on the Use and Misuse of Bleeding Risk Scores.
This article is protected by copyright. All rights reserved. PMID: 27296528 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 13, 2016 Category: Hematology Authors: Lip GY, Lane DA Tags: J Thromb Haemost Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One-year outcomes from the GReek AntiPlatelet Registry (GRAPE).
CONCLUSIONS: In real-word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events. This article is protected by copyright. All rights reserved. PMID: 26990959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 16, 2016 Category: Hematology Authors: Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros P, Hahalis G, Goudevenos J Tags: J Thromb Haemost Source Type: research

D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
We examined baseline levels of D-dimer and their association with stroke, cardiovascular death and major bleeding in 6,202 AF patients randomised to dabigatran or warfarin in the RE-LY trial. The effects of treatment on serial levels of D-dimer and coagulation factor (F) VIIa in 2,567 patients were also analysed. Baseline D-dimer levels were related to the rate of stroke/systemic embolism (SEE) with 0.64 % in the lowest quartile (Q1, as reference) (D-dimer < 298 µg/l), 1.38 % Q2 (D-dimer 298-473 µg/l), 1.71 % Q3 (D-dimer 474-822 µg/l) and 2.00 % in Q4 (D-dimer > 822 µg/l) (p=0.0007). Similar associati...
Source: Thrombosis and Haemostasis - January 28, 2016 Category: Hematology Authors: Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW Tags: Thromb Haemost Source Type: research

Impact of point-of-care INR monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study.
CONCLUSIONS: Although associated with lower TTR, point-of-care INR monitoring is a safe and effective alternative to laboratory INR monitoring in non-self-monitoring patients on vitamin K antagonists. This article is protected by copyright. All rights reserved. PMID: 26806724 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 25, 2016 Category: Hematology Authors: Biedermann JS, van Rein N, van den Besselaar AM, Buhre PN, de Maat MP, van der Meer FJ, Leebeek FW, Kruip MJ Tags: J Thromb Haemost Source Type: research